Loop Diuretics in Clinical Practice.
Article Details
- CitationCopy to clipboard
Oh SW, Han SY
Loop Diuretics in Clinical Practice.
Electrolyte Blood Press. 2015 Jun;13(1):17-21. doi: 10.5049/EBP.2015.13.1.17. Epub 2015 Jun 30.
- PubMed ID
- 26240596 [ View in PubMed]
- Abstract
Diuretics are commonly used to control edema across various clinical fields. Diuretics inhibit sodium reabsorption in specific renal tubules, resulting in increased urinary sodium and water excretion. Loop diuretics are the most potent diuretics. In this article, we review five important aspects of loop diuretics, in particular furosemide, which must be considered when prescribing this medicine: (1) oral versus intravenous treatment, (2) dosage, (3) continuous versus bolus infusion, (4) application in chronic kidney disease patients, and (5) side effects. The bioavailability of furosemide differs between oral and intravenous therapy. Additionally, the threshold and ceiling doses of furosemide differ according to the particular clinical condition of the patient, for example in patients with severe edema or chronic kidney disease. To maximize the efficiency of furosemide, a clear understanding of how the mode of delivery will impact bioavailability and the required dosage is necessary.
DrugBank Data that Cites this Article
- Drugs
- Drug Interactions
Drugs Interaction Integrate drug-drug
interactions in your softwareFurosemideCyclosporine The risk or severity of gouty arthritis can be increased when Cyclosporine is combined with Furosemide. IvabradineTorasemide The risk or severity of Cardiac Arrhythmia can be increased when Torasemide is combined with Ivabradine. IvabradineFurosemide The risk or severity of Cardiac Arrhythmia can be increased when Furosemide is combined with Ivabradine. IvabradineBumetanide The risk or severity of Cardiac Arrhythmia can be increased when Bumetanide is combined with Ivabradine. IvabradineEtacrynic acid The risk or severity of Cardiac Arrhythmia can be increased when Etacrynic acid is combined with Ivabradine.